Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips For anyone suffering from gastric or gastroesophageal junction cancer, a recent breakthrough from Leap Therapeutics (NASDAQ: LPTX ) has yielded seemingly promising results for a method of treatment. This morning, the ...
Gainers: Itamar Medical ITMR +45%, aTyr Pharma LIFE +35%, iRhythm Technologies (NASDAQ:IRTC) +33%, REGENXBIO RGNX +20%, Leap Therapeutics LPTX +15%. Losers: MiMedx MDXG -61%, Silverback Therapeutics (NASDAQ:SBTX) -24%, Dynavax T...
Itamar Medical (NASDAQ:ITMR) +44% on being taken over by Zoll Medical for ~$538M Leap Therapeutics (NASDAQ:LPTX) +42% to present new data from the DisTinGuish study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congres BELLUS Health (NASDAQ:BLU) +24% positive interim f...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! The weekend has come and gone and that means it’s time to get back into investing with a look at Monday’s biggest pre-market stock movers. Source: f11photo/Shutterstock.com We...
Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress - DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer - In pa...
Are These Penny Stocks On Your List Right Now? In this article, we will take a look at 4 penny stocks with upcoming events very soon. How do we know this? One of the great things about certain industries is that companies will pre-announced key dates well in advance. Biotech companies a...
Leap Therapeutics to Participate at Two Upcoming Virtual Investor Conferences PR Newswire CAMBRIDGE, Mass. , Sept. 7, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology thera...
Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation PR Newswire CAMBRIDGE, Mass. , Aug. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and imm...
EyeGate Pharmaceuticals EYEG +127% names Brian Strem CEO, proposes $7M Bayon dealObsEva SA OBSV +28%, Organon ink ebopiprant licensing deal for preterm laborOrbsat Corp. (OSAT) +27%.MOGU Inc. (MOGU) +21% announces entry into Definitive Agreements to increase ownershi...
Leap Therapeutics to Present at the ESMO 2021 Virtual Congress PR Newswire CAMBRIDGE, Mass. , July 26, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today ...
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...